Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast

Cell proliferation was assessed in 33 invasive breast carcinomas by an immunoperoxidase procedure using the monoclonal antibody, Ki‐67, which reacts with a nuclear antigen in proliferating cells. The antibody labeled a variable proportion of tumor cells ranging from 3% to 60%. High numbers of Ki‐67‐...

Full description

Saved in:
Bibliographic Details
Published inCancer Vol. 59; no. 10; pp. 1744 - 1750
Main Authors McGurrin, John F., Doria, Manuel I., Dawson, Peter J., Karrison, Theodore, Stein, Harald O., Franklin, Wilbur A.
Format Journal Article
LanguageEnglish
Published New York Wiley Subscription Services, Inc., A Wiley Company 15.05.1987
Wiley-Liss
Subjects
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Biological and medical sciences
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Carcinoma - metabolism
Carcinoma - pathology
Cell Cycle
Female
Gynecology. Andrology. Obstetrics
Histocytochemistry
Humans
Immunoenzyme Techniques
Lymphatic Metastasis
Mammary gland diseases
Medical sciences
Middle Aged
Prognosis
Receptors, Estrogen - analysis
Tumors
Human
Immunohistochemistry
Mammary gland diseases
Carcinoma
Tumor
Kinetics
Mammary gland
Tumor cell
Online AccessGet full text

Cover

More Information
Summary:Cell proliferation was assessed in 33 invasive breast carcinomas by an immunoperoxidase procedure using the monoclonal antibody, Ki‐67, which reacts with a nuclear antigen in proliferating cells. The antibody labeled a variable proportion of tumor cells ranging from 3% to 60%. High numbers of Ki‐67‐positive cells were found in tumors with high mitotic rates, high nuclear grade, high histologic grade, and in premenopausal women. Tumors with low and intermediate Ki‐67 labeling rates often had high estrogen receptor content, whereas tumors with high Ki‐67 labeling rates were usually estrogen receptor negative. These correlations are similar to those previously reported for other measurements of cell cycle kinetics such as thymidine labeling index and suggest that immunohistochemical staining of invasive breast carcinoma for the Ki‐67 epitope may provide cell cycle information not otherwise readily available to the clinician and may be useful in assessing prognosis in carcinoma of the breast.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19870515)59:10<1744::AID-CNCR2820591012>3.0.CO;2-D